Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAN HF: LINQ Impedance Sensitivity Study
NCT03245281Phase 4Unknown
- Sponsor
- Medtronic
- Start
- Oct 2017
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
Phase 4, open-label trial (3 arms), sponsored by Medtronic. Primary endpoint: Derived-subcutaneous impedance magnitude at 2 months. Status: unknown.
Beyond the preview
Go deeper on NCT03245281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245281.